190 related articles for article (PubMed ID: 38326661)
21. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
[TBL] [Abstract][Full Text] [Related]
22. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
23. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
24. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
Suchorska B; Giese A; Biczok A; Unterrainer M; Weller M; Drexler M; Bartenstein P; Schüller U; Tonn JC; Albert NL
Neuro Oncol; 2018 Jan; 20(2):279-288. PubMed ID: 29016996
[TBL] [Abstract][Full Text] [Related]
25. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D
J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.
Waqar M; Hanif S; Brodbelt AR; Rathi N; Das K; Zakaria R; Walker C; Jenkinson MD
World Neurosurg; 2015 Jul; 84(1):154-62. PubMed ID: 25779854
[TBL] [Abstract][Full Text] [Related]
27. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
28. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
29. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.
Morshed RA; Han SJ; Hervey-Jumper SL; Pekmezci M; Troncon I; Chang SM; Butowski NA; Berger MS
J Neurooncol; 2019 Jan; 141(2):383-391. PubMed ID: 30498891
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
[TBL] [Abstract][Full Text] [Related]
31. Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.
Familiari P; Lapolla P; Picotti V; Palmieri M; Pesce A; Carosi G; Relucenti M; Nottola S; Gianno F; Minasi S; Antonelli M; Frati A; Santoro A; D'Andrea G; Bruzzaniti P; LA Pira B
Anticancer Res; 2023 Jun; 43(6):2659-2670. PubMed ID: 37247932
[TBL] [Abstract][Full Text] [Related]
32. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
33. Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
Kim M; Kim S; Park YW; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurooncol; 2022 Sep; 159(3):695-703. PubMed ID: 35988090
[TBL] [Abstract][Full Text] [Related]
34. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
35. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
[TBL] [Abstract][Full Text] [Related]
36. Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system.
Delev D; Heiland DH; Franco P; Reinacher P; Mader I; Staszewski O; Lassmann S; Grau S; Schnell O
J Neurooncol; 2019 Jan; 141(1):223-233. PubMed ID: 30467813
[TBL] [Abstract][Full Text] [Related]
37. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
[TBL] [Abstract][Full Text] [Related]
38. Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma.
Belyaev AY; Kobyakov GL; Shmakov PN; Telysheva EN; Strunina YV; Usachev DY
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(5):21-27. PubMed ID: 36252190
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
40. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]